These funds will be used to initiate a proof-of-concept study of the CRTH2 antagonist OC459 in severe eosinophilic asthma, and to accelerate the development of both OC459 and
CAT-1004 is an oral small-molecule that the Company believes has the potential to be a disease-modifying therapy for DMD patients, regardless of the underlying dystrophin mutation, by inhibiting
Altius (higher in Latin) will be pioneering new technologies and approaches for decoding how genes are controlled and how a cell’s "operating system" functions in health and disease.
LBI is an internationally renowned organization dedicated to research in the fields of tissue engineering, stem cells, and regenerative medicine. "Collaborating with the Ludwig Boltzmann Institute gives Hemostemix
AKP-11 is a novel First-in-Class topical Sphingosine 1-Phosphate receptor-1 (S1P1) modulator for the treatment of mild-to-moderate plaque psoriasis in patients. Patients will be treated daily for six weeks
"The orphan drug designation for XOMA 358 recognizes its potential to address a significant unmet medical need for patients with congenital hyperinsulinism. Patients with hyperinsulinism, a rare and
This patent expands the intellectual property for the Company’s opioid abuse deterrent technology. Elite now has four US patents and two Canadian patents issued in this area with
Founders Giorgos Tsetis, a fashion model and engineer and Roland Peralta, a beauty and fashion executive suffered from hair loss and sought integrative and holistic solutions. They assembled
A first for the company, the new supplement contains the well-researched and highly efficacious probiotic strain, Lactobacillus plantarum 299v (LP299V), which can withstand the stomach’s acidic environment allowing
The products meet all U.S. regulatory requirements. The highly popular Superburn and T-300 have long appealed to consumers interested in safe and effective ways to manage their weight,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.